Pharma’s Productivity Problem: Finding More Blockbuster Drugs
Xconomy
AUGUST 16, 2016
A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry. With a limited supply of new firms coming into the business, venture’s ability to expand to meet demand is inherently constrained.
Let's personalize your content